In addition, the randomized phase 4 Japan EPA Lipid Intervention Study (JELIS) investigated the use of EPA plus a HMG-CoA reductase inhibitor in the treatment of patients with concurrent hypertriglyceridemia [20]. Here, HMGCR is linked to hypertriglyceridemia.